RxDoctor Payments Data

Kristin Evans, NP

Family · Chattanooga, TNNPI 1104286467

Payments from drug & device makers

$2,199in general payments, 2019–2025

Across 86 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$500
  • Biohaven Pharmaceutical Holding Company Ltd.$349
  • Novo Nordisk$150
  • Pfizer$127
  • Takeda Pharmaceuticals U.S.A., Inc.$116
  • Abbott$111
  • plus $845 from 22 others

What the payments were for

  • Food & beverage$2,18799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,199 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$45,174
Medicare patients
150
Services billed
2,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol73$78,037
OzempicSemaglutide70$76,993
MounjaroTirzepatide27$37,752
ProliaDenosumab14$23,530
JardianceEmpagliflozin12$20,628
JanuviaSitagliptin Phosphate12$17,489
EliquisApixaban19$13,985
TrulicityDulaglutide15$13,956
Atorvastatin Calcium184$2,408
Albuterol Sulfate HfaAlbuterol Sulfate58$1,903
Famotidine102$1,778
Omeprazole117$1,669
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine17$1,433
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$1,285
Levothyroxine Sodium191$1,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$19$78,03773 claims
Novo NordiskOzempic$150$76,99370 claims
Lilly USA, LLCMounjaro, Trulicity$108$51,70842 claims
AmgenProlia$18$23,53014 claims
MerckJanuvia$65$17,48912 claims
PfizerEliquis$127$13,98519 claims
AbbVieSynthroid$500$76317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →